X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-08-20 | GILD | Gilead Sciences, Inc. | Bluestone Jeffrey | Dir | S - Sale+OE | $145.02 | -5,000 | 10,066 | -33% | -$725,078 | |||||
| DM | 2026-08-20 | NMRA | Neumora Therapeutics, Inc. | Aurora Daljit Singh | See Remarks | S - Sale+OE | $1.53 | -176,060 | 48,750 | -78% | -$269,967 | |||||
| D | 2026-08-19 | FDMT | 4D Molecular Therapeutics, Inc. | Kirn David | See Remarks | S - Sale+OE | $15.75 | -69,076 | 825,819 | -8% | -$1,088,273 | |||||
| D | 2026-08-20 | RGEN | Repligen Corp | Loeillot Olivier | CEO | S - Sale+OE | $180.00 | -5,426 | 54,246 | -9% | -$976,680 | |||||
2026-08-19 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $129.75 | -14,205 | 75,661 | -16% | -$1,843,099 | ||||||
2026-08-20 | HUMA | Humacyte, Inc. | Jones Keith Anthony | Dir | P - Purchase | $0.69 | +10,000 | 40,000 | +33% | +$6,930 | ||||||
2026-08-20 | IMVT | Immunovant, Inc. | Gloria Melanie | COO | S - Sale | $44.16 | -3,056 | 219,301 | -1% | -$134,953 | ||||||
| D | 2026-08-18 | ADPT | Adaptive Biotechnologies Corp | Hershberg Robert | Dir | S - Sale+OE | $24.40 | -30,664 | 46,683 | -40% | -$748,208 | |||||
| M | 2026-08-18 | PROK | Prokidney Corp. | Pereira Brian Jg | Dir | S - Sale | $1.41 | -757,164 | 0 | -100% | -$1,067,773 | |||||
| D | 2026-08-18 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale+OE | $117.64 | -78,355 | 214,678 | -27% | -$9,217,607 | |||||
| D | 2026-08-18 | ARTV | Artiva Biotherapeutics, Inc. | Banerjee Subhashis | Chief Medical Officer | S - Sale+OE | $12.00 | -429 | 144,963 | 0% | -$5,148 | |||||
| DM | 2026-08-17 | ADPT | Adaptive Biotechnologies Corp | Robins Chad M | CEO, COB | S - Sale+OE | $24.80 | -600,000 | 2,180,518 | -22% | -$14,882,166 | |||||
| D | 2026-08-17 | ADPT | Adaptive Biotechnologies Corp | Neupert Peter M | Dir | S - Sale+OE | $25.15 | -124,690 | 130,625 | -49% | -$3,135,850 | |||||
| DM | 2026-08-17 | HALO | Halozyme Therapeutics, Inc. | Torley Helen | Pres, CEO | S - Sale+OE | $104.59 | -60,000 | 767,780 | -7% | -$6,275,592 | |||||
| DM | 2026-08-17 | NMRA | Neumora Therapeutics, Inc. | Aurora Daljit Singh | See Remarks | S - Sale+OE | $1.55 | -277,773 | 48,750 | -85% | -$431,674 | |||||
2026-08-17 | REPL | Replimune Group, Inc. | Hill Emily Luisa | CFO | S - Sale | $14.28 | -9,256 | 215,852 | -4% | -$132,176 | ||||||
2026-08-18 | LXEO | Lexeo Therapeutics, Inc. | Tamayo Louis Edward | CFO | S - Sale | $4.91 | -4,117 | 92,907 | -4% | -$20,203 | ||||||
2026-08-18 | LXEO | Lexeo Therapeutics, Inc. | Townsend Richard Nolan | CEO | S - Sale | $4.95 | -3,345 | 374,472 | -1% | -$16,562 | ||||||
2026-08-18 | LXEO | Lexeo Therapeutics, Inc. | Otero Jose Manuel | COO | S - Sale | $4.96 | -1,304 | 136,178 | -1% | -$6,464 | ||||||
2026-08-17 | CADL | Candel Therapeutics, Inc. | Tyagarajan Seshu | CTO | S - Sale | $12.00 | -7,000 | 76,865 | -8% | -$84,000 | ||||||
2026-08-17 | HUMA | Humacyte, Inc. | Jones Keith Anthony | Dir | P - Purchase | $0.59 | +30,000 | 30,000 | New | +$17,820 | ||||||
2026-08-18 | MGTX | Meiragtx Holdings Plc | Forbes Alexandria | Pres, CEO | S - Sale | $13.86 | -62,000 | 1,325,695 | -4% | -$859,320 | ||||||
| DM | 2026-08-17 | IVVD | Invivyd, Inc. | Lee Timothy Edward | Chief Commercial Officer | S - Sale+OE | $0.78 | -40,780 | 178,937 | -19% | -$31,671 | |||||
| DM | 2026-08-17 | IVVD | Invivyd, Inc. | Green Julie | CHRO | S - Sale+OE | $0.78 | -40,780 | 168,937 | -19% | -$31,671 | |||||
| DM | 2026-08-17 | IVVD | Invivyd, Inc. | Duke William E. | CFO | S - Sale+OE | $0.78 | -40,780 | 168,937 | -19% | -$31,671 | |||||
| DM | 2026-08-17 | IVVD | Invivyd, Inc. | Andersen Jill | GC, Secretary | S - Sale+OE | $0.78 | -67,962 | 284,274 | -19% | -$52,781 | |||||
| DM | 2026-08-17 | IVVD | Invivyd, Inc. | Allen Robert D. III | Chief Scientific Officer | S - Sale+OE | $0.78 | -37,722 | 178,765 | -17% | -$29,296 | |||||
2026-08-17 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $138.36 | -3,000 | 165,646 | -2% | -$415,080 | ||||||
| D | 2026-08-17 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Comm, Corp Aff Officer | S - Sale+OE | $137.64 | -28,000 | 118,234 | -19% | -$3,853,908 | |||||
| D | 2026-08-14 | CGON | Cg Oncology, Inc. | Post Leonard E | Dir | S - Sale+OE | $74.54 | -1,000 | 0 | -100% | -$74,540 | |||||
2026-08-17 | RLAY | Relay Therapeutics, Inc. | Patel Sanjiv | Pres, CEO | S - Sale | $20.33 | -48,199 | 1,454,602 | -3% | -$979,886 | ||||||
2026-08-14 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | CFO | S - Sale | $19.74 | -17,717 | 140,568 | -11% | -$349,734 | ||||||
2026-08-17 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $0.93 | +5,400 | 381,115 | +1% | +$5,022 | ||||||
2026-08-17 | TNYA | Tenaya Therapeutics, Inc. | Ali Faraz | CEO | S - Sale | $0.71 | -22,232 | 417,782 | -5% | -$15,778 | ||||||
2026-08-17 | TNYA | Tenaya Therapeutics, Inc. | Tingley Whittemore | Chief Medical Officer | S - Sale | $0.71 | -7,424 | 214,073 | -3% | -$5,270 | ||||||
| DM | 2026-08-13 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | GC | S - Sale+OE | $12.10 | -3,270 | 8,617 | -28% | -$39,567 | |||||
| D | 2026-08-14 | OTLK | Outlook Therapeutics, Inc. | Jahr Robert Charles | CEO | P - Purchase | $0.00 | +151,515 | 151,515 | New | +$0 | |||||
| D | 2026-08-12 | OTLK | Outlook Therapeutics, Inc. | Sukhtian Ghiath M. | Dir, 10% | P - Purchase | $0.99 | +2,525,252 | 24,617,320 | +11% | +$2,499,999 | |||||
| D | 2026-08-14 | OTLK | Outlook Therapeutics, Inc. | Kenyon Lawrence A | CFO | P - Purchase | $0.00 | +101,010 | 106,956 | >999% | +$0 | |||||
| D | 2026-08-12 | TECX | Tectonic Therapeutic, Inc. | McNamara Peter | Chief Scientific Officer | S - Sale+OE | $35.00 | -43 | 55,285 | 0% | -$1,505 | |||||
2026-08-14 | KRYS | Krystal Biotech, Inc. | Rossi Dino A | Dir | S - Sale | $329.12 | -25,000 | 50,000 | -33% | -$8,227,953 | ||||||
| D | 2026-08-13 | CGEM | Cullinan Therapeutics, Inc. | Michaelson Jennifer | Chief Scientific Officer | S - Sale+OE | $20.26 | -30,000 | 162,844 | -16% | -$607,800 | |||||
| D | 2026-08-13 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Pres, R, D, CMO | S - Sale+OE | $27.61 | -16,142 | 0 | -100% | -$445,621 | |||||
2026-08-12 | TWST | Twist Bioscience Corp | Blake Katryn | Dir | S - Sale | $122.88 | -2,240 | 17,208 | -12% | -$275,251 | ||||||
| D | 2026-08-12 | VCEL | Vericel Corp | McLaughlin Kevin F | Dir | S - Sale+OE | $44.53 | -7,000 | 18,300 | -28% | -$311,710 | |||||
| D | 2026-08-12 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $125.08 | -19,952 | 818,938 | -2% | -$2,495,508 | |||||
| DM | 2026-08-05 | ATTO | Attovia Therapeutics, Inc. | Walsh Colin | Dir | P - Purchase | $17.58 | +585,000 | 3,020,632 | +24% | +$10,285,000 | |||||
| D | 2026-08-05 | ATTO | Attovia Therapeutics, Inc. | Walsh Colin | Dir | S - Sale+OE | $21.28 | -105,807 | 3,020,632 | -3% | -$2,251,658 | |||||
| DM | 2026-08-11 | AMGN | Amgen Inc | Khosla Rachna | SVP, Business Development | S - Sale+OE | $414.05 | -3,252 | 6,404 | -34% | -$1,346,499 | |||||
2026-08-13 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $0.92 | +1,900 | 375,785 | +1% | +$1,748 | ||||||
2026-08-11 | DNLI | Denali Therapeutics Inc. | Schuth Alexander O. | COFO, Secretary | S - Sale | $25.07 | -2,857 | 805,512 | 0% | -$71,625 | ||||||
2026-08-12 | XFOR | X4 Pharmaceuticals, Inc | Volpone John | Pres | S - Sale | $4.44 | -24,576 | 265,305 | -8% | -$109,228 | ||||||
2026-08-12 | XFOR | X4 Pharmaceuticals, Inc | Craig Adam R | Exec COB | S - Sale | $4.44 | -47,436 | 328,651 | -13% | -$210,829 | ||||||
2026-08-10 | EXEL | Exelixis, Inc. | Beckerle Mary C | Dir | S - Sale | $53.66 | -9,812 | 16,079 | -38% | -$526,512 | ||||||
2026-08-10 | ADPT | Adaptive Biotechnologies Corp | Bobulsky Susan | Chief Commercial Officer, MRD | S - Sale | $25.00 | -3,000 | 396,989 | -1% | -$75,000 | ||||||
2026-08-10 | REPL | Replimune Group, Inc. | Patel Sushil | CEO | S - Sale | $12.97 | -39,341 | 708,151 | -5% | -$510,253 | ||||||
2026-08-10 | REPL | Replimune Group, Inc. | Hill Emily Luisa | CFO | S - Sale | $12.97 | -11,448 | 225,108 | -5% | -$148,481 | ||||||
2026-08-10 | REPL | Replimune Group, Inc. | Xynos Konstantinos | Chief Medical Officer | S - Sale | $12.97 | -11,447 | 224,215 | -5% | -$148,468 | ||||||
2026-08-10 | REPL | Replimune Group, Inc. | Schwendenman Andrew | Chief Accounting Officer | S - Sale | $12.97 | -7,632 | 99,425 | -7% | -$98,987 | ||||||
| D | 2026-08-10 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $125.16 | -113,318 | 818,938 | -12% | -$14,183,051 | |||||
2026-08-10 | HALO | Halozyme Therapeutics, Inc. | Connaughton Bernadette | Dir | S - Sale | $102.80 | -1,626 | 40,418 | -4% | -$167,153 | ||||||
| D | 2026-08-07 | TWST | Twist Bioscience Corp | Chess Robert | Dir | S - Sale+OE | $110.89 | -18,417 | 63,612 | -22% | -$2,042,261 | |||||
| D | 2026-08-06 | ATTO | Attovia Therapeutics, Inc. | Venbio Global Strategic Fund Iv, L.P. | 10% | P - Purchase | $17.00 | +382,352 | 4,181,367 | +10% | +$6,499,984 | |||||
| D | 2026-08-06 | ATTO | Attovia Therapeutics, Inc. | Redmile Group, LLC | 10% | P - Purchase | $17.00 | +600,000 | 2,165,708 | +38% | +$10,200,000 | |||||
| D | 2026-08-05 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale+OE | $134.17 | -5,500 | 168,498 | -3% | -$737,935 | |||||
| D | 2026-08-06 | AMGN | Amgen Inc | Miller Derek | SVP, HR | S - Sale+OE | $402.54 | -3,890 | 12,462 | -24% | -$1,565,898 | |||||
| D | 2026-08-06 | AMGN | Amgen Inc | Grygiel Nancy A. | SVP, CCO | S - Sale+OE | $402.16 | -2,970 | 7,447 | -29% | -$1,194,415 | |||||
| A | 2026-07-21 | OKYO | Okyo Pharma Ltd | Brancaccio John P | Dir | P - Purchase | $1.48 | +5,000 | 35,201 | +17% | +$7,385 | |||||
| A | 2026-07-22 | OKYO | Okyo Pharma Ltd | Dempsey Robert John | CEO | P - Purchase | $1.54 | +15,000 | 15,000 | New | +$23,085 | |||||
| A | 2026-07-21 | OKYO | Okyo Pharma Ltd | Jacob Gary S | CHIEF DEVELOPMENT OFFICER | P - Purchase | $1.40 | +3,500 | 112,420 | +3% | +$4,900 | |||||
| A | 2026-07-21 | OKYO | Okyo Pharma Ltd | Cerrone Gabriele M | Dir, 10% | P - Purchase | $1.45 | +22,500 | 10,873,916 | 0% | +$32,625 | |||||
| A | 2026-07-20 | OKYO | Okyo Pharma Ltd | Cerrone Gabriele M | Dir, 10% | P - Purchase | $1.40 | +25,000 | 10,851,416 | 0% | +$35,000 | |||||
| A | 2026-07-21 | OKYO | Okyo Pharma Ltd | Mantelli Flavio | CHIEF MEDICAL OFFICER | P - Purchase | $1.40 | +20,000 | 20,000 | New | +$28,000 | |||||
| A | 2026-07-27 | OKYO | Okyo Pharma Ltd | Patil Rajkumar V. | Chief Scientific Officer | P - Purchase | $1.49 | +3,363 | 20,030 | +20% | +$5,011 | |||||
| D | 2026-08-05 | MRNA | Moderna, Inc. | Bancel Stephane | CEO | S - Sale+OE | $57.52 | -499,246 | 22,215,826 | -2% | -$28,715,011 | |||||
2026-08-05 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $109.75 | -14,205 | 89,866 | -14% | -$1,558,999 | ||||||
| D | 2026-08-06 | ATTO | Attovia Therapeutics, Inc. | Frazier Life Sciences Xi, L.P. | 10% | P - Purchase | $17.00 | +588,235 | 6,154,213 | +11% | +$9,999,995 | |||||
2026-08-04 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $3.25 | -30,000 | 6,188,287 | 0% | -$97,500 | ||||||
| D | 2026-08-05 | PCVX | Vaxcyte, Inc. | Dhaliwal Harpreet S. | Chief Technical Ops Officer | S - Sale+OE | $55.00 | -17,000 | 76,756 | -18% | -$935,068 | |||||
| D | 2026-08-03 | PCVX | Vaxcyte, Inc. | Wassil Jim | COO | S - Sale+OE | $53.86 | -2,250 | 157,541 | -1% | -$121,195 | |||||
| D | 2026-08-03 | PCVX | Vaxcyte, Inc. | Guggenhime Andrew | Pres, CFO | S - Sale+OE | $53.89 | -10,000 | 167,026 | -6% | -$538,879 | |||||
2026-08-04 | FDMT | 4D Molecular Therapeutics, Inc. | Kirn David | See Remarks | S - Sale | $10.23 | -26,842 | 844,895 | -3% | -$274,596 | ||||||
2026-08-03 | MAZE | Maze Therapeutics, Inc. | Coloma Jason V | CEO | S - Sale | $26.73 | -34,501 | 276,007 | -11% | -$922,315 | ||||||
2026-08-03 | IPSC | Century Therapeutics, Inc. | Carr Douglas | SVP Finance, Operations | S - Sale | $1.98 | -275 | 504,819 | 0% | -$544 | ||||||
2026-08-03 | EDIT | Editas Medicine, Inc. | Parison Amy | SVP, CFO | S - Sale | $2.58 | -678 | 14,292 | -5% | -$1,749 | ||||||
| D | 2026-08-03 | VCEL | Vericel Corp | Halpin Michael | COO | S - Sale+OE | $46.84 | -10,000 | 16,394 | -38% | -$468,400 | |||||
2026-08-03 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $85.32 | -2,888 | 269,678 | -1% | -$246,408 | ||||||
2026-08-03 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $85.32 | -1,133 | 119,281 | -1% | -$96,669 | ||||||
| D | 2026-08-03 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $85.32 | -5,101 | 818,938 | -1% | -$435,223 | |||||
2026-08-03 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $85.32 | -167 | 46,160 | 0% | -$14,249 | ||||||
2026-08-03 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $85.32 | -1,070 | 104,071 | -1% | -$91,294 | ||||||
2026-08-04 | FATE | Fate Therapeutics Inc | Tahl Cindy | See Remarks | S - Sale | $2.46 | -38,800 | 589,355 | -6% | -$95,405 | ||||||
| M | 2026-08-03 | BIIB | Biogen Inc. | Minor Lloyd | Dir | S - Sale | $202.15 | -1,186 | 2,689 | -31% | -$239,750 | |||||
2026-08-04 | FATE | Fate Therapeutics Inc | Valamehr Bahram | Pres, CEO | S - Sale | $2.46 | -43,947 | 591,815 | -7% | -$108,101 | ||||||
2026-08-03 | GILD | Gilead Sciences, Inc. | O'Day Daniel Patrick | COB, CEO | S - Sale | $130.31 | -15,000 | 592,133 | -2% | -$1,954,694 | ||||||
| M | 2026-07-31 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% | P - Purchase | $8.00 | +52,900 | 3,148,223 | +2% | +$422,976 | |||||
2026-08-03 | FDMT | 4D Molecular Therapeutics, Inc. | Kirn David | See Remarks | S - Sale | $10.05 | -12,415 | 871,737 | -1% | -$124,722 | ||||||
2026-08-03 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | Former Director | S - Sale | $9.58 | -10,000 | 131,633 | -7% | -$95,800 | ||||||
2026-07-30 | ADPT | Adaptive Biotechnologies Corp | Bobulsky Susan | Chief Commercial Officer, MRD | S - Sale | $24.00 | -1,299 | 399,989 | 0% | -$31,176 | ||||||
| M | 2026-07-29 | ARTV | Artiva Biotherapeutics, Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $9.96 | +45,768 | 18,489,293 | 0% | +$455,726 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |